RDHL — RedHill Biopharma Ltd.

Summary of RedHill Biopharma's Q1 2022 Earnings Call

1. Key Financial Results and Metrics

• Net Revenues: $18.2 million, down from $22.1 million in Q4 2021, attributed to cyclical trends in Movantik sales.
• Gross Profit: $10.2 million, reflecting a gross margin of 56%.
• Operating Loss: Reduced significantly, with cash used in operating activities decreasing over 70% to approximately $4 million compared to $15 million in Q4 2021.
• Cash Position: Approximately $45 million as of March 31, 2022, bolstered by a $15 million direct offering in May 2022.
• Cost Reduction Plan: Aiming for operational cost savings of approximately $50 million over the next 18 months.

2. Strategic Updates and Business Highlights

• Cost Control Initiatives: A comprehensive cost reduction plan was implemented, including a 33% reduction in the U.S. commercial team workforce and streamlining operational expenditures.
• Commercial Performance: Record quarterly prescription volumes achieved for Movantik and Talicia. Movantik maintained a 74% market share in the PAMORA class, while Talicia grew prescription volume by 12.8% over Q4 2021.
• R&D Focus: Continued development of COVID-19 candidates opaganib and RHB-107, with plans to seek external funding for R&D activities.
• Market Positioning: Talicia is positioned as the leading branded H. pylori therapy in the U.S., with improved payer coverage.

3. Forward Guidance and Outlook

• Profitability Target: Targeting positive cash flow from operations in the second half of 2022.
• Sales Growth: Continued growth expected for Movantik and Talicia, supported by enhanced market access and payer coverage.
• R&D Funding: Plans to pursue non-dilutive funding sources for ongoing R&D programs, particularly in COVID-19 therapeutics and NTM disease.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The decrease in net revenues compared to the previous quarter raises concerns about sales sustainability.
• Competitive Pressures: New entrants in the H. pylori treatment market could impact Talicia's sales, although management remains confident in its competitive advantages.
• Workforce Reduction: The significant reduction in the commercial team may affect sales coverage and operational capacity in the short term.
• Market Uncertainties: The evolving nature of the COVID-19 pandemic presents ongoing challenges for the development and commercialization of related therapeutics.

5. Notable Q&A Insights

• Commercial Team Reduction: Management clarified that territories previously covered by reduced staff would be managed through remaining representatives and customer engagement specialists.
• Gross to Net Comparison: The company expects gross to net ratios to stabilize, with improvements anticipated due to increased coverage.
• Pathway for Opaganib: Regulatory pathways for opaganib may include confirmatory studies for emergency use authorization, depending on pandemic conditions.
• RHB-204 Funding: Discussions for external funding are ongoing, which could accelerate patient enrollment and study timelines for NTM treatments.

Overall, RedHill Biopharma is navigating a challenging market environment with a focus on cost reduction and operational profitability while maintaining growth in its core therapeutic areas.